Peter J Zimetbaum MD
Cardiac Electrophysiology
Associate Chief and Clinical Director, Cardiology Division Beth Israel Deaconess Medical Center
Join to View Full Profile
185 Pilgrim RdBaker 4Boston, MA 02215
Phone+1 617-632-9209
Dr. Zimetbaum is on Doximity
As a Doximity member you'll join over two million verified healthcare professionals in a private, secure network.
- Gain access to free telehealth tools, such as our “call shielding” and one-way patient texting.
- Connect with colleagues in the same hospital or clinic.
- Read the latest clinical news, personalized to your specialty.
Summary
- Richard and Susan Smith Professor of Cardiovascular Medicine, Harvard Medical School
Education & Training
Beth Israel Deaconess Medical CenterFellowship, Clinical Cardiac Electrophysiology, 1996 - 1997- Beth Israel Deaconess Medical CenterFellowship, Clinical Cardiac Electrophysiology, 1995 - 1997
- Beth Israel Deaconess Medical CenterFellowship, Cardiovascular Disease, 1993 - 1996
- Beth Israel Deaconess Medical CenterChief Residency, Internal Medicine, 1994 - 1995
- Beth Israel Deaconess Medical CenterFellowship, Cardiovascular Disease, 1993 - 1994
- Beth Israel Deaconess Medical CenterResidency, Internal Medicine, 1990 - 1993
- Beth Israel Deaconess Medical CenterInternship, Internal Medicine, 1990 - 1991
Albert Einstein College of MedicineClass of 1990
Certifications & Licensure
MA State Medical License 1992 - 2025
American Board of Internal Medicine Cardiovascular Disease- American Board of Internal Medicine Clinical Cardiac Electrophysiology
Awards, Honors, & Recognition
- Boston Magazine Castle Connolly, 2012-2013
- Meaningful Use Stage 1 Certification Centers for Medicare & Medicaid Services, 2011
- Super Doctor SuperDoctors.com
- Join now to see all
Clinical Trials
- Atrial Fibrillation Rate Control Therapy Guided By Continuous Ambulatory Monitoring Start of enrollment: 2005 Apr 01
- Safety Study on Stopping Anticoagulation Medication in Patients With a History of Atrial Fibrillation Start of enrollment: 2013 Jan 01
- Rhythm Evaluation for AntiCoagulaTion With COntinuous Monitoring Start of enrollment: 2012 Oct 01
- Join now to see all
Publications & Presentations
PubMed
- 1 citationsSafety and behavior of implantable electronic devices during cremation.Timothy Maher, Nathan Kong, Ryan Spray, Sophie Lee, Sofia Gurgel
Heart Rhythm. 2025-04-01 - Mortality and readmissions after ventricular tachycardia ablation: An analysis of inpatient and outpatient state databases.Peter G Brodeur, Enrico G Ferro, Timothy G Maher, Jonathan W Waks, Andre d'Avila
Heart Rhythm. 2025-03-12 - Quantitative Microbial Cell-Free DNA Sequencing from Plasma: A Potential Biomarker for the Diagnosis of Staphylococcal Infection of Cardiac Implantable Electronic Devi...Adolf W Karchmer, N Jenifer Kaufman, Sarah Y Park, Ronuk M Modi, Ahmed Abdul-Azim
Clinical Infectious Diseases. 2025-03-11
Lectures
- Unmet Need for Rhythm Disturbance After TAVR: Practical Strategies for the Interventional Cardiologist2019 ACC Scientific Session & Expo, New Orleans - 3/17/2019
- Case 4 Debate: Patient With RV Lead and TR: The Extractionist's View2019 ACC Scientific Session & Expo, New Orleans - 3/16/2019
Other
- Risk of QT Interval Prolongation Associated with Use of Hydroxychloroquine with or Without Concomitant Azithromycin Among Hospitalized Patients Testing Positive for Co...Peter Zimetbaum, MD, JAMA Cardiology
https://www.doximity.com/articles/40a5a553-d61c-4d1d-9f58-9aa5e4a77fe2
UpToDate, Wolters Kluwer Health - 2012-11-16 - Prognosis of nonsustained VT in the presence of structural heart diseaseZimetbaum PJ, Wylie JV, Josephson ME
http://www.uptodate.com/contents/prognosis-of-nonsustained-vt-in-the-presence-of-structural-heart-di
UpToDate, Wolters Kluwer Health - 2012-09-21
Authored Content
- Risk of QT Interval Prolongation Associated with Use of Hydroxychloroquine with or Without Concomitant Azithromycin Among Hospitalized Patients Testing Positive for Coronavirus Disease 2019 (COVID-19)May 2020
Press Mentions
Pacemaker Complication Rate Four Times Higher Than ExpectedMay 23rd, 2023- Apixaban Appears Safer, More Effective Than Rivaroxaban in Medicare StudyDecember 27th, 2021
- More Ischemic, Hemorrhagic Events Seen with Rivaroxaban Than ApixabanDecember 22nd, 2021
- Join now to see all
Professional Memberships
- Fellow
- Fellow
- Fellow
Viewing the full profile is available to verified healthcare professionals only.
Find your profile and take control of your online presence:
